Goodwin @ JPMorgan

Our 2nd Virtual Goodwin + KPMG @ JPMorgan Symposium attracted the interest of over 900 people from the industry and over 400 attendees over the course of two days. We devoted this program to accelerated innovation in the life sciences industry that has been galvanized exponentially because of the global COVID-19 pandemic. Topics covered at this event included:

  • What will 2021 and beyond look like in this new reality?
  • Looking forward, how is accelerated innovation in the industry a silver lining?
  • Who and what are the catalysts for change, and why?
  • What is the future of deal making and how will deals get done?

Our Life Sciences and Healthcare teams attended the presentations at the virtual J.P. Morgan Healthcare Conference in January and provided a first-hand report to attendees of our 2nd Annual Goodwin + KPMG @ JPMorgan Symposium.

We welcomed Noubar Afeyan, Chairman and Co-Founder of Moderna and Founder and CEO of Flagship Pioneering, as well as Carl Hansen, CEO and Tryn Stimart, Chief Legal Officer of AbCellera, who participated in fireside chats during our Symposium, as well as industry leaders, investors and investment bankers from Altimmune, Parexel Biotech, TrialSpark, Weill Cornell Medicine, Sesame Health, Novartis, Flare Capital Partners, Fountain Healthcare Partners, and Lazard who participated in the panel discussions. 

Wednesday, January 27, 2021

JPMorgan 2021

Day 1: The COVID Catalyst

We kicked off the Symposium with industry luminary, Noubar Afeyan, Chairman and Co-Founder of Moderna, which attracted a record 260 viewers. We continued the day with three industry-focused panels, starting with a panel on how COVID-19 boosted innovation across the continuum whether it be devices, therapeutics, diagnostics, supply chain, or the dissemination of needed products and services on a worldwide scale. The second panel addressed how digital health came into the spotlight in 2020 as a result of increased demand for virtual health. We closed the first day with a panel that discussed how the 2020 SPACs revolution will impact the IPO Market for 2021 and beyond.

Panel Titles: 

  • Fireside Chat with Noubar Afeyan, Chairman and Co-Founder of Moderna and Founder and CEO of Flagship Pioneering 
  • The COVID Catalyst: Driving Innovation Mainstream
  • COVID Gives Digital Health a Shot in the Arm
  • How the 2020 SPACs Revolution Will Impact the IPO Market for 2021 and Beyond

View the Video:

Thursday, January 28, 2021

JPMorgan 2021

Day 2: COVID Effects on the Life Sciences Industry 

We kicked off the second day with an overview of the effects of the pandemic on the biopharma market by Dale Raine, Managing Director and Co-Head of European Healthcare Investment Banking at Lazard, followed by a panel discussing the global life sciences outlook, partnerships and M&A opportunities, and whether Europe will continue to be a focus for 2021 and beyond. We wrapped up our Symposium by sitting down for a fireside chat with the CEO of AbCellera, Carl Hansen and their Chief Legal Officer, Tryn Stimart, discussing drug discovery and the accelerated adoption of AI and machine learning in our new reality, and their path to one of the largest IPOs in biotech history.

Panel Titles: 

  • What Innovation in the Biopharma Market Will Look Like in the Post-COVID Era
  • Global Life Sciences Outlook 2021
  • Fireside Chat with Carl Hansen, CEO and Tryn Stimart, CLO of AbCellera: Drug Discovery and Accelerated Adoption of AI and Machine Learning in our New Reality

View the Video: 

2020 Goodwin + KPMG @ JPMorgan Symposium Highlights


On Wednesday, January 15, 2020, during the J.P. Morgan Healthcare conference, Goodwin and KPMG held their initial all-day Symposium at the St. Regis hotel in San Francisco. The Symposium was composed of five separate “bursts” entitled (i) New Frontiers in Digital Diagnostics and MedTech, (ii) Europe Unleashed, (iii) Knowing the Best IPO Strategy, (iv) Trends in Biopharma and (v) Mergers and Acquisitions. Stéphane Bancel, the Chief Executive Officer of Moderna Therapeutics, provided the keynote address.


Goodwin's Life Sciences Practice

Goodwin knows that succeeding in the life sciences industry is as much about strategy and execution as it is about research and development. In this highly competitive business, you need more than the best and brightest ideas - you need a legal and strategic partner that understands the challenges of securing funding, safeguarding intellectual property, establishing partnerships, bringing new products to market, opening up new revenue streams, and protecting existing products line.

Goodwin can help. We know the market, the players and the science. With a full service team of highly experienced lawyers resident in key life sciences hubs, Goodwin helps clients find the strategic paths that foster growth and minimize risk across all phases of the corporate life cycle.

Click here to learn more about Gooodwin's Life Sciences practice.

Case Studies

Recent News

Life Sciences Perspectives

Goodwin’s Life Sciences Perspectives Blog is a resource specifically aimed at addressing your most frequent and pressing issues and providing insights on current developments. The challenges across the life sciences industry are as abundant as the opportunities. From tightening federal regulations and market forces to revolutionary innovations, the headwinds are stiff and shifting but they are navigable. We will be tracking emerging issues and developments on private and public company matters, licensing deals and collaborations, patent and IP matters, FDA and healthcare regulatory compliance, and European and Asian developments for life sciences companies. Read the Life Sciences Perspectives Blog >>
Life Sciences Perspectives